Connect Biopharma Holdings (CNTB) Depreciation & Amortization (CF) (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted quarterly Depreciation & Amortization (CF) of $164000.0 for Q1 2026, down 5.2% year-on-year from $173000.0 in Q1 2025, and down 9.39% on a QoQ basis from $181000.0 in Q4 2025.
Connect Biopharma Holdings (CNTB) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $164000.0 the latest figure, recorded in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.2% year-over-year to $164000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $695000.0 (up 3.89% YoY) and the FY2025 annual result came in at $704000.0, up 6.67% from the prior year.
- Depreciation & Amortization (CF) retreated to $164000.0 in Q1 2026 per CNTB's latest filing, from $181000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for CNTB reached as high as $181000.0 in Q4 2025 and fell as low as $158000.0 in Q4 2024.
- A 3-year average of $169777.8 and a median of $171000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) advanced 14.56% — and 2026, when it decreased 5.2%.
- Year by year, Depreciation & Amortization (CF) stood at $158000.0 in 2024, then advanced by 14.56% to $181000.0 in 2025, then fell by 9.39% to $164000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $164000.0, $181000.0, and $179000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Connect Biopharma Holdings | 120.44 Mn | 120.44 Mn | - | 164,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164,000.00 |
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | 179,000.00 |
| Sep 30, 2025 | 179,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Mar 31, 2025 | 173,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Dec 31, 2024 | 158,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Mar 31, 2024 | 164,000.00 |
| Mar 31, 2024 | 164,000.00 |